Trial Profile
An Open-Label Trial of Vesicare (Solifenacin Succinate) for the Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2012
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 22 Mar 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 22 Mar 2012 Actual end date (Oct 2011) added as reported by University Hospital Medical Information Network - Japan.
- 10 May 2011 New trial record